Blog
About

11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Superior overall survival of patients with myeloma achieving very good partial response or better to initial treatment with bortezomib, pegylated liposomal doxorubicin, and dexamethasone, predicted after two cycles by a free light chain- and M-protein-based model: extended follow-up of a phase II trial.

      Leukemia & Lymphoma

      Treatment Outcome, Antineoplastic Combined Chemotherapy Protocols, Survival Analysis, administration & dosage, Pyrazines, Prognosis, Polyethylene Glycols, metabolism, Myeloma Proteins, mortality, drug therapy, diagnosis, Multiple Myeloma, Models, Statistical, blood, Immunoglobulin Light Chains, Humans, Follow-Up Studies, analogs & derivatives, Doxorubicin, Dexamethasone, Boronic Acids, therapeutic use

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          In myeloma, achievement of very good partial response (VGPR) post-transplant is associated with prolonged overall (OS) and progression-free survival (PFS). In this study of bortezomib, pegylated liposomal doxorubicin, and dexamethasone (VDD) in 40 patients with newly diagnosed myeloma (median follow-up 45.1 months), 2-/4-year OS estimates were 95.7%/86.5% versus 82.4%/58.2% for patients achieving ≥VGPR versus 

          Related collections

          Author and article information

          Journal
          10.3109/10428194.2011.567316
          21699382

          Comments

          Comment on this article